Author details

Full Name

Gunther Boysen

Affiliation

ORCID

Career Start Year

2008

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36265504	Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study.	Lancet Oncol	2022
34753775	HER3 Is an Actionable Target in Advanced Prostate Cancer.	Cancer Res	2021
33016930	Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma.	J Clin Invest	2020
31433989	Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate Cancer.	Cell Rep	2019
30257982	RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer.	Clin Cancer Res	2019
29500065	Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).	Eur Urol	2018
30068710	SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.	Clin Cancer Res	2018
30382943	Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.	J Clin Invest	2018
30093450	Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis.	Clin Cancer Res	2018
30042009	Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer.	Clin Colorectal Cancer	2018
30179225	Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.	J Clin Invest	2018
29555663	Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).	Clin Cancer Res	2018
27590317	DNA Repair in Prostate Cancer: Biology and Clinical Implications.	Eur Urol	2017
28383660	CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair.	Ann Oncol	2017
28450425	Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.	Cancer Discov	2017
28751446	Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification.	Clin Cancer Res	2017
28068321	Analysis of DNA methylation in single circulating tumor cells.	Oncogene	2017
27753448	The molecular underpinnings of prostate cancer: impacts on management and pathology practice.	J Pathol	2017
26374986	SPOP mutation leads to genomic instability in prostate cancer.	Elife	2015
26510020	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.	N Engl J Med	2015
23622249	Punctuated evolution of prostate cancer genomes.	Cell	2013
22610119	Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.	Nat Genet	2012
22806541	Identification and functional characterization of pVHL-dependent cell surface proteins in renal cell carcinoma.	Neoplasia	2012
20028743	Mining tissue microarray data to uncover combinations of biomarker expression patterns that improve intermediate staging and grading of clear cell renal cell cancer.	Clin Cancer Res	2010
18660794	Sporadic clear cell renal cell carcinoma but not the papillary type is characterized by severely reduced frequency of primary cilia.	Mod Pathol	2009
19401348	Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma.	Clin Cancer Res	2009
19581925	Onconeuronal cerebellar degeneration-related antigen, Cdr2, is strongly expressed in papillary renal cell carcinoma and leads to attenuated hypoxic response.	Oncogene	2009
19862527	[Identification of VHL-associated changes in clear cell renal carcinoma: the application of combined genome and expression analyses].	Pathologe	2009
18751980	[Von-Hippel-Lindau gene mutation types. Association of gene expression signatures in clear cell renal cell carcinoma].	Pathologe	2008